Affiliations: [a] Zhang Zhongjing College of Chinese Medicine, Nanyang Institute of Technology, Nanyang, Henan, China
| [b] Department of Pharmacy, First Affiliated hospital of Zhengzhou University, Zhengzhou, Henan, China
| [c] Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China
Correspondence:
[*]
Corresponding author: Jingke Yang, Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, %Zhengzhou, Henan, China. Dongming Road 127, Zhengzhou 450008, Henan, China. E-mail: yangjingke@gmail.com
Abstract:
BACKGROUND: Multi-drug resistance (MDR) remains to be a major
obstacle toward successful chemotherapy of NHL patients. P-glycoprotein
(P-gp), a classical protein associated with MDR, has been observed in
peripheral blood CD56 + cells with high expression and activity. While
the CD56 expression has been shown to be associated with a highly aggressive
clinical course and chemoresistance in Non-Hodgkin lymphoma (NHL).
OBJECTIVE: To investigate the role of peripheral blood CD56 +
cells in predicting the MDR of NHL by determining the P-gp expression and
function of the CD56 + cells.
METHODS: The expression levels of MDR1 mRNA and MRP1 mRNA and the function
of P-gp in the CD56 + cells were evaluated by RT-qPCR and flow
cytometry respectively in 52 chemoresistant and 47 chemosensitive NHL
patients and 48 healthy donors.
RESULTS: In the chemoresistant group, the mRNA expression level of
MDR1 elevated about 2∼ 8 fold (mean = 4.24 ± 0.17) in the purified CD56^+
cells, whereas there was only about 1∼ 2.5 fold (mean = 1.69 ± 0.41)
elevated for the MRP1 gene. The mean fold change of MDR1 mRNA expression in the
chemoresistant group significantly increased when compared with that in the
chemosensitive patients (P < 0.001). The mean fluorescence intensities (MFI)
in the total gated CD56^{ + } and Rho123 double positive cells in the
chemoresistant patients statistically decreased compared with that in the
healthy controls and the chemosensitive NHL patients (P < 0.01).
CONCLUSIONS: Determining the P-gp expression and function of the
peripheral blood CD56^{ + } cells may help predict the MDR of NHL, thus
has profound guiding significance for NHL treatment.
